SciClone Pharmaceuticals

About:

SciClone Pharmaceuticals is a pharmaceutical company.

Website: http://www.sciclone.com

Top Investors: Opportunity Fund, IDG Capital, Grand View Capital, Shanghai Pharmaceutical

Description:

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.

Total Funding Amount:

$134M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Foster City, California, United States

Founded Date:

1990-01-01

Contact Email:

roesterle(AT)sciclone.com

Founders:

Li Zhenfu

Number of Employees:

501-1000

Last Funding Date:

2021-02-19

IPO Status:

Public

Industries:

© 2025 bioDAO.ai